Executive Editorial Board
GaBI Journal’s Executive Editorial Board comprises the Editor-in-Chief, Deputy Editors-in-Chief, Associate Editors, and Publisher.
Editor-in-Chief
Dr Robin Thorpe, PhD, FRCPath, Former Head of Biotherapeutics Group, National Institute for Biological Standards and Control, UK
Deputy Editor-in-Chief
Dr Robert Janknegt, PharmD, PhD, Director of Pharmacy, Orbis Medical Centre; Advisory Pharmacist, CZ Insurance Company, The Netherlands
Emeritus Editor-in-Chief
Professor Philip D Walson, MD, Board Certified in Paediatrics, Clinical Pharmacology and Medical Toxicology, USA. Visiting Professor, Institute for Clinical Chemistry, University Medical Center at Georg-August-University Medical School, Göttingen, Germany
Associate Editors
Professor Huub Schellekens, MD, Member of MEB, Professor of Medical Biotechnology, Utrecht University, The Netherlands
Professor Steven Simoens, PhD, Professor of Pharmacoeconomics, University of Leuven, Belgium
Publisher
Ms Lasia Tang, Belgium
Expert Editorial Board with Associate Editors portfolios for:
- Bioequivalence methodology (traditional and biopharmaceutical)
- Biopharmaceutical production/manufacturing methodology
- Regulatory issues around generics and biopharmaceuticals, including national medicines boards’ perspective
- Clinical trials
- Stability studies
- General drug development
- Healthcare policies, medicines policies, and health economics
- Special patient populations, such as children, elderly, obese
- Drug safety and risk management